|
|
Prepublished online as a Blood First Edition Paper on February 6, 2003; DOI 10.1182/blood-2002-09-2780.
 Previous Article | Table of Contents | Next Article 
Blood, 15 June 2003, Vol. 101, No. 12, pp. 4701-4707
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
Ravi Bhatia,
Melissa Holtz,
Ning Niu,
Rachel Gray,
David S. Snyder,
Charles L. Sawyers,
Daniel A. Arber,
Marilyn L. Slovak, and
Stephen J. Forman
From the Division of Hematology and Bone Marrow Transplantation and Division of Pathology, City of Hope National Medical Center, Duarte, CA; and Division of Hematology and Oncology, University of California at Los Angeles, CA.
The BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) has shown remarkable efficacy in the treatment of chronic myelogenous leukemia (CML), with a high proportion of patients achieving complete cytogenetic responses (CCRs). However, it is not clear whether remissions will be durable and whether imatinib mesylate can eliminate the malignant primitive progenitors in which the disease arises. We investigated whether residual BCR/ABL+ hematopoietic progenitors were present in patients who achieved CCRs with imatinib mesylate treatment. CD34+ progenitor cells were selected from bone marrow mononuclear cells (MNCs) and analyzed for the presence of the BCR/ABL fusion gene by fluorescence in situ hybridization (FISH). CD34+ cells were also plated in committed progenitor (colony-forming cell, or CFC) and primitive progenitor (long-term bone marrow culture-initiating cell, or LTCIC) cultures and resulting colonies analyzed for the presence of BCR/ABL+ cells by FISH. Using these assays, residual BCR/ABL+ progenitors were detected in all patients studied. Quantitative reverse transcriptase–polymerase chain reaction (RT-PCR) analysis demonstrated increased levels of BCR/ABL mRNA in CD34+ cells compared with total MNCs. Evaluation of samples collected at different time points demonstrated persistence of BCR/ABL+ progenitors despite continued treatment with imatinib mesylate. Our results indicate that inhibition of BCR/ABL tyrosine kinase activity by imatinib mesylate does not eliminate malignant primitive progenitors in CML patients. Patients in CCR with imatinib mesylate treatment need to be followed carefully to assess for risk of relapse.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. S. M. Yong, K. Keyvanfar, N. Hensel, R. Eniafe, B. N. Savani, M. Berg, A. Lundqvist, S. Adams, E. M. Sloand, J. M. Goldman, et al.
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib
Blood,
January 22, 2009;
113(4):
875 - 882.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Motiwala, S. Majumder, K. Ghoshal, H. Kutay, J. Datta, S. Roy, D. M. Lucas, and S. T. Jacob
PTPROt Inactivates the Oncogenic Fusion Protein BCR/ABL and Suppresses Transformation of K562 Cells
J. Biol. Chem.,
January 2, 2009;
284(1):
455 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Bixby and M. Talpaz
Imatinib As Frontline Therapy for Patients with Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia
ASCO Educational Book,
January 1, 2009;
2009(1):
395 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Kolb
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Blood,
December 1, 2008;
112(12):
4371 - 4383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Konig, T. L. Holyoake, and R. Bhatia
Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606
Blood,
February 15, 2008;
111(4):
2329 - 2338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Klion, J. Robyn, I. Maric, W. Fu, L. Schmid, S. Lemery, P. Noel, M. A. Law, M. Hartsell, C. Talar-Williams, et al.
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing
Blood,
November 15, 2007;
110(10):
3552 - 3556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Scheich, J. Duyster, C. Peschel, and H. Bernhard
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens
Blood,
October 1, 2007;
110(7):
2556 - 2560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chu, L. Li, H. Singh, and R. Bhatia
BCR-Tyrosine 177 Plays an Essential Role in Ras and Akt Activation and in Human Hematopoietic Progenitor Transformation in Chronic Myelogenous Leukemia
Cancer Res.,
July 15, 2007;
67(14):
7045 - 7053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. M. Yong, K. Rezvani, B. N. Savani, R. Eniafe, S. Mielke, J. M. Goldman, and A. J. Barrett
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects
Blood,
July 15, 2007;
110(2):
770 - 775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Volpe, A. Cignetti, C. Panuzzo, M. Kuka, K. Vitaggio, M. Brancaccio, G. Perrone, M. Rinaldi, G. Prato, M. Fava, et al.
Alternative BCR/ABL Splice Variants in Philadelphia Chromosome-Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches
Cancer Res.,
June 1, 2007;
67(11):
5300 - 5307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Rodrigues and M. Sattler
Chronic Myelogenous Leukemia Progenitors Display a Genetically Unstable Personality
J Natl Cancer Inst,
May 2, 2007;
99(9):
662 - 663.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Jiang, K. M. Saw, A. Eaves, and C. Eaves
Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells
J Natl Cancer Inst,
May 2, 2007;
99(9):
680 - 693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saudemont, A. Hamrouni, P. Marchetti, J. Liu, N. Jouy, D. Hetuin, F. Colucci, and B. Quesnel
Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1
Cancer Res.,
May 1, 2007;
67(9):
4491 - 4498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Michor
Chronic Myeloid Leukemia Blast Crisis Arises from Progenitors
Stem Cells,
May 1, 2007;
25(5):
1114 - 1118.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. G. Jorgensen, E. K. Allan, N. E. Jordanides, J. C. Mountford, and T. L. Holyoake
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells
Blood,
May 1, 2007;
109(9):
4016 - 4019.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Wang, D. Cai, C. Brendel, C. Barett, P. Erben, P. W. Manley, A. Hochhaus, A. Neubauer, and A. Burchert
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation
Blood,
March 1, 2007;
109(5):
2147 - 2155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Holtz, S. J. Forman, and R. Bhatia
Growth Factor Stimulation Reduces Residual Quiescent Chronic Myelogenous Leukemia Progenitors Remaining after Imatinib Treatment
Cancer Res.,
February 1, 2007;
67(3):
1113 - 1120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kometani, M. Aoki, S. Kawamata, Y. Shinozuka, T. Era, M. Taniwaki, M. Hattori, and N. Minato
Role of SPA-1 in Phenotypes of Chronic Myelogenous Leukemia Induced by BCR-ABL-Expressing Hematopoietic Progenitors in a Mouse Model.
Cancer Res.,
October 15, 2006;
66(20):
9967 - 9976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kuroda, H. Puthalakath, M. S. Cragg, P. N. Kelly, P. Bouillet, D. C. S. Huang, S. Kimura, O. G. Ottmann, B. J. Druker, A. Villunger, et al.
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
PNAS,
October 3, 2006;
103(40):
14907 - 14912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Kaufmann
Imatinib spells BAD news for Bcr/abl-positive leukemias
PNAS,
October 3, 2006;
103(40):
14651 - 14652.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood,
September 15, 2006;
108(6):
1809 - 1820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shimizu, M. Hidaka, N. Kadowaki, N. Makita, N. Konishi, K. Fujimoto, T. Uchiyama, F. Kawano, M. Taniguchi, and S.-i. Fujii
Evaluation of the Function of Human Invariant NKT Cells from Cancer Patients Using {alpha}-Galactosylceramide-Loaded Murine Dendritic Cells.
J. Immunol.,
September 1, 2006;
177(5):
3484 - 3492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Quintas-Cardama and J. E. Cortes
Chronic Myeloid Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
July 1, 2006;
81(7):
973 - 988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Talpaz, N. P. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, J. Cortes, S. O'Brien, C. Nicaise, E. Bleickardt, et al.
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
N. Engl. J. Med.,
June 15, 2006;
354(24):
2531 - 2541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Copland, A. Hamilton, L. J. Elrick, J. W. Baird, E. K. Allan, N. Jordanides, M. Barow, J. C. Mountford, and T. L. Holyoake
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Blood,
June 1, 2006;
107(11):
4532 - 4539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Copelan
Hematopoietic stem-cell transplantation.
N. Engl. J. Med.,
April 27, 2006;
354(17):
1813 - 1826.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. G. Jorgensen, M. Copland, E. K. Allan, X. Jiang, A. Eaves, C. Eaves, and T. L. Holyoake
Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor In vitro Promotes their Elimination by Imatinib Mesylate
Clin. Cancer Res.,
January 15, 2006;
12(2):
626 - 633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, H. Kantarjian, S. O'Brien, M. B. Rios, L. Abruzzo, S. Verstovsek, G. Garcia-Manero, and J. Cortes
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
Blood,
January 15, 2006;
107(2):
480 - 482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. M. Yong, R. M. Szydlo, J. M. Goldman, J. F. Apperley, and J. V. Melo
Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML
Blood,
January 1, 2006;
107(1):
205 - 212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Lange, T. Thielsen, S. Leiblein, R. Alt, G. Zschau, R. Burckhardt, I. Kovacz, H. K. Al-Ali, C. Franke, R. Krahl, et al.
Comparable Distribution of Minimal Residual Diesease between CD34 Positive Hematopoietic Progenitors, CD34 Negative Cells and Total White Cells in Patients with Chronic Myeloid Leukemia (CML) in Molecular Response.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
1985 - 1985.
[Abstract]
|
|
|
|
|
|
|
F. Y. Lee, M.-L. Wen, A. Camuso, S. Castenada, K. Fager, C. Flefleh, I. Inigo, R. Luo, D. Kan, V. Manne, et al.
Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
1993 - 1993.
[Abstract]
|
|
|
|
|
|
|
A. Ibatici, G. Fugazza, N. Sessarego, M. Podesta, S. Agliano, S. Pozzi, M. Corselli, A. Garuti, M. Sessarego, and F. Frassoni
Molecular Responders (<3-log Reduction) among CML Patients in Complete Cytogenetic Remission Show a Lower Number of BCR-ABL+ Hematopoietic Progenitors Compared to Non-Responders.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
4325 - 4325.
[Abstract]
|
|
|
|
|
|
|
S. Appel, S. Balabanov, T. H. Brummendorf, and P. Brossart
Effects of Imatinib on Normal Hematopoiesis and Immune Activation
Stem Cells,
September 1, 2005;
23(8):
1082 - 1088.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Li, Y. Qiao, B. Liu, E. J. Laska, P. Chakravarthi, J. M. Kulko, R. D. Bona, M. Fang, U. Hegde, V. Moyo, et al.
Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia
Clin. Cancer Res.,
June 15, 2005;
11(12):
4460 - 4468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Wolff, D. R. Veach, W. P. Tong, W. G. Bornmann, B. Clarkson, and R. L. Ilaria Jr
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia
Blood,
May 15, 2005;
105(10):
3995 - 4003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Elrick, H. G. Jorgensen, J. C. Mountford, and T. L. Holyoake
Punish the parent not the progeny
Blood,
March 1, 2005;
105(5):
1862 - 1866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chu, H. Xu, N. P. Shah, D. S. Snyder, S. J. Forman, C. L. Sawyers, and R. Bhatia
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment
Blood,
March 1, 2005;
105(5):
2093 - 2098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Ilaria Jr.
Pathobiology of Lymphoid and Myeloid Blast Crisis and Management Issues
Hematology,
January 1, 2005;
2005(1):
188 - 194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Yin, Y.-L. Wu, H.-P. Sun, G.-L. Sun, Y.-Z. Du, K.-K. Wang, J. Zhang, G.-Q. Chen, S.-J. Chen, and Z. Chen
Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein
Blood,
December 15, 2004;
104(13):
4219 - 4225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Wong, J. McLaughlin, D. Cheng, C. Zhang, K. M. Shokat, and O. N. Witte
Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations
PNAS,
December 14, 2004;
101(50):
17456 - 17461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saudemont and B. Quesnel
In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis
Blood,
October 1, 2004;
104(7):
2124 - 2133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ramaraj, H. Singh, N. Niu, S. Chu, M. Holtz, J. K. Yee, and R. Bhatia
Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors
Cancer Res.,
August 1, 2004;
64(15):
5322 - 5331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mohty, E. Jourdan, N. B. Mami, N. Vey, G. Damaj, D. Blaise, D. Isnardon, D. Olive, and B. Gaugler
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia
Blood,
June 15, 2004;
103(12):
4666 - 4668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chu, M. Holtz, M. Gupta, and R. Bhatia
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells
Blood,
April 15, 2004;
103(8):
3167 - 3174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Klion, J. Robyn, C. Akin, P. Noel, M. Brown, M. Law, D. D. Metcalfe, C. Dunbar, and T. B. Nutman
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome
Blood,
January 15, 2004;
103(2):
473 - 478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Bartolovic, S. Balabanov, U. Hartmann, M. Komor, A. M. Boehmler, H.-J. Buhring, R. Mohle, D. Hoelzer, L. Kanz, W.-K. Hofmann, et al.
Inhibitory effect of imatinib on normal progenitor cells in vitro
Blood,
January 15, 2004;
103(2):
523 - 529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Antin
A 41-Year-Old Woman With Chronic Myelogenous Leukemia
JAMA,
August 27, 2003;
290(8):
1083 - 1090.
[Full Text]
[PDF]
|
|
|
|
|
